Cue Biopharma, Inc. (CUE): Price and Financial Metrics


Cue Biopharma, Inc. (CUE): $14.91

0.77 (+5.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CUE POWR Grades


  • CUE scores best on the Sentiment dimension, with a Sentiment rank ahead of 58.01% of US stocks.
  • The strongest trend for CUE is in Momentum, which has been heading down over the past 48 weeks.
  • CUE's current lowest rank is in the Momentum metric (where it is better than 4.42% of US stocks).

CUE Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CUE is 0.08 -- better than just 10.94% of US stocks.
  • With a price/sales ratio of 81.43, Cue Biopharma Inc has a higher such ratio than 96.2% of stocks in our set.
  • With a year-over-year growth in debt of -42.19%, Cue Biopharma Inc's debt growth rate surpasses only 11.95% of about US stocks.
  • Stocks that are quantitatively similar to CUE, based on their financial statements, market capitalization, and price volatility, are APTX, SWTX, ARVN, TBPH, and ACRS.
  • CUE's SEC filings can be seen here. And to visit Cue Biopharma Inc's official web site, go to www.cuebiopharma.com.

CUE Valuation Summary

  • In comparison to the median Healthcare stock, CUE's price/earnings ratio is 123.56% lower, now standing at -8.6.
  • CUE's price/sales ratio has moved NA NA over the prior 45 months.
  • Over the past 45 months, CUE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CUE.

Stock Date P/S P/B P/E EV/EBIT
CUE 2021-08-31 69.1 5.2 -8.6 -7.0
CUE 2021-08-30 69.1 5.2 -8.6 -7.0
CUE 2021-08-27 71.3 5.4 -8.9 -7.3
CUE 2021-08-26 66.7 5.0 -8.3 -6.7
CUE 2021-08-25 67.6 5.1 -8.4 -6.8
CUE 2021-08-24 63.9 4.8 -8.0 -6.4

CUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CUE has a Quality Grade of D, ranking ahead of 18.46% of graded US stocks.
  • CUE's asset turnover comes in at 0.057 -- ranking 314th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CUE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.057 1 -4.121
2021-03-31 0.038 1 -2.398
2020-12-31 0.034 1 -1.802
2020-09-30 0.044 1 -1.622
2020-06-30 0.058 1 -1.826
2020-03-31 0.073 1 -2.258

CUE Price Target

For more insight on analysts targets of CUE, see our CUE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.83 Average Broker Recommendation 1.17 (Strong Buy)

CUE Stock Price Chart Interactive Chart >

Price chart for CUE

CUE Price/Volume Stats

Current price $14.91 52-week high $17.23
Prev. close $14.14 52-week low $9.65
Day low $14.05 Volume 444,808
Day high $15.63 Avg. volume 336,592
50-day MA $11.39 Dividend yield N/A
200-day MA $12.71 Market Cap 469.78M

Cue Biopharma, Inc. (CUE) Company Bio


Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company’s biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


CUE Latest News Stream


Event/Time News Detail
Loading, please wait...

CUE Latest Social Stream


Loading social stream, please wait...

View Full CUE Social Stream

Latest CUE News From Around the Web

Below are the latest news stories about Cue Biopharma Inc that investors may wish to consider to help them evaluate CUE as an investment opportunity.

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Patents Further Strengthen and Enhance Intellectual Property (IP) PortfolioCAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body, announced today the issuance of two new United States Patents Nos. 11,117,945 and 11,104,712 from the United States Patent and Trademark Office. U.S. Patent No. 11,11

Yahoo | September 21, 2021

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in two fireside chats, Baird's 2021 Global Healthcare Conference, September 14-15 and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20-23, 2021. Both confe

Yahoo | September 9, 2021

Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?

A look at the shareholders of Cue Biopharma, Inc. ( NASDAQ:CUE ) can tell us which group is most powerful. Institutions...

Yahoo | August 23, 2021

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, provided a business and clinical progress update for the second quarter 2021.

Intrado Digital Media | August 17, 2021

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will host a conference call and webcast to provide a business update on Tuesday, August 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Companys website .

Intrado Digital Media | August 10, 2021

Read More 'CUE' Stories Here

CUE Price Returns

1-mo 34.32%
3-mo 10.77%
6-mo 27.76%
1-year -1.58%
3-year 62.95%
5-year N/A
YTD 19.18%
2020 -21.20%
2019 237.77%
2018 N/A
2017 N/A
2016 N/A

Continue Researching CUE

Here are a few links from around the web to help you further your research on Cue Biopharma Inc's stock as an investment opportunity:

Cue Biopharma Inc (CUE) Stock Price | Nasdaq
Cue Biopharma Inc (CUE) Stock Quote, History and News - Yahoo Finance
Cue Biopharma Inc (CUE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9981 seconds.